Abstract
Introduction
Deep brain stimulation (DBS) is currently approved only to treat Parkinson's
disease and Parkinson-like symptoms; however, clinical trials are under way
for DBS in several other neurological and psychiatric disorders. As these
surgical interventions gain acceptance in the face of conventional therapies'
shortcomings in severely affected patients, opportunities are emerging for
such devices, used both alone and in conjunction with existing drug regimens.
Get the Answers You Need to Shape Your Strategy
Currently, DBS is approved only for parkinsonism. For what other
indications is DBS being investigated? What advantages does DBS offer to treat
these indications? What potential exists for DBS in these indications? The
risk factors associated with DBS have made it a last-resort therapy for most
indications. How competitive will DBS be with conventional drug therapies?
In which indications will it stand out? Will DBS ever be used as an early
therapy, in any indication? Medtronic is the only company to have an
approved device for DBS, although several companies have devices in
development for other indications. Which of the companies developing DBS
devices is best positioned to succeed in these new markets? What innovations
must these companies provide to ensure success? Which company is poised to
collaborate with drugmakers in creating a viable combination therapy?
| 
View Cart
